Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bismuth

Phase 3Small molecule

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Bismuth is one of 58 small molecule programs targeting Toxicity. It is currently in Phase 3.

4

Indications

26

Total Trials

4

Active Trials

57

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Microscopic ColitisActive, not recruiting

Helicobatcer PyloriNot yet recruiting

Bismuth Quadruple TherapyUnknown status

ToxicityPreclinical

Active, not recruiting

Microscopic ColitisPreclinical

Active, not recruiting

Helicobatcer PyloriPreclinical

Not yet recruiting

Bismuth Quadruple TherapyPhase 3

Unknown status

Competition

Competitive Landscape

62 competitors in Toxicity

#DrugCompanyPhaseTrials

Norvir

Zyvox

Oncovin

Aldactone

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Ativan

BBausch Health Americas, Inc.

Vancocin

HHikma Pharmaceuticals LLC

Jardiance

Boehringer Ingelheim

Prezista

Cubicin

BBaxter Healthcare Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Helicobacter Pylori Infection

NCT06731023

Q3 2029

PreclinicalNot yet recruiting

Helicobatcer Pylori

NCT07788053

Clinical

Trials by Indication[1]

Helicobacter Pylori Eradication7 trials

Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05237115·600 enrolled

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

Completed·—·Phase 4·NCT00841854·199 enrolled

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT02296021·612 enrolled

Show 4 more trials

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT02633930·566 enrolled

Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05742568·124 enrolled

Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial

Recruiting·YYongquan Shi·Phase 4·NCT07068607·400 enrolled

Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04697186·524 enrolled

Helicobacter3 trials

Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT03609892·658 enrolled

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·YYongquan Shi·Phase 4·NCT06168084·688 enrolled

Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04678492·658 enrolled

Helicobacter Pylori Infection2 trials

Empirical Rescue Therapies of Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01668927·424 enrolled

Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study

Not yet recruiting·XXiuli Zuo··NCT06731023·30 enrolled

Interaction2 trials

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

Unknown status·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04444011·32 enrolled

Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin

Completed·SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.·Phase 1·NCT05915871·22 enrolled

Helicobacter Pylori2 trials

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

Completed·SSeoul National University Bundang Hospital·N/A·NCT02159976·390 enrolled

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01667718·161 enrolled

8 more indications

Bismuth Quadruple Therapy2 trials

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Recruiting·YYongquan Shi·Phase 4·NCT07139366·1,248 enrolled

Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.

Unknown status·XXijing Hospital of Digestive Diseases·Phase 4·NCT06603688·548 enrolled

Efficacy and Safety2 trials

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05014334·300 enrolled

Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT06514274·558 enrolled

Toxicity1 trial

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?

Completed·—·N/A·NCT00892502·50 enrolled

Oral1 trial

Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers

Completed·HHK inno.N Corporation·Phase 1·NCT04066257·32 enrolled

Gastric1 trial

Intragastric pH and Bismuth Effect for H. Pylori Eradication

Completed·NNational Taiwan University Hospital·N/A·NCT02894892·21 enrolled

Randomized Controlled Trial1 trial

Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial

Completed·ZZhongshan Hospital (Xiamen), Fudan University·N/A·NCT06977841·640 enrolled

Microscopic Colitis1 trial

Treatment of Microscopic Colitis

Terminated·NNorwegian University of Science and Technology·N/A·NCT00184171·105 enrolled

Helicobatcer Pylori1 trial

Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple Versus Bismuth Quadruple Therapies For First-Line Eradication of Helicobacter Pylori Infection: A Single-Center, Randomized Controlled Trial

Not yet recruiting·CChih-An Shih, MD·Preclinical·NCT07788053·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Bismuth. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bismuth compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bismuth. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Related News